Shutdown Notice: Unfortunately I have shut down the Earnings Calls app and website. My data provider shut down their service and I couldn't find a viable alternative. If you purchased the iPhone app and feel like you didn't get your money's worth, please request a refund via the App Store. As a replacement, many brokerage services are adding earnings calls to their apps (like Robinhood, for example) or try Earningscast. Thank you to everyone who supported and enjoyed Earnings Calls, I'm sorry to let you down. – Justin Thiele

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of desensitization treatments for peanut and other food allergies. Its Characterized Oral Desensitization Immunotherapy includes AR101, a product in Phase 3 registration trial for the treatment of peanut allergy in children and adults. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. The company was founded in 2011 and is headquartered in Brisbane, California.

AIMT Conference Calls / Webcasts:

Date Time (Eastern) Title
  2/16/17 5:00 pm Aimmune Therapeutics Inc Call to Discuss The Announced AR101 Program Updates
  11/04/16 8:00 am Aimmune Therapeutics Inc Call to Discuss the Nestlé Health Science Investment and Collaboration
  8/22/16 4:30 pm Aimmune Therapeutics Inc Call to Discuss the Publication of the DEVIL study data and potential implications for development of AR101
  6/13/16 4:00 pm Aimmune Therapeutics Inc Management Call on Late-Breaker Presentation at the EAACI
  3/03/16 5:00 pm Aimmune Therapeutics Inc Earnings (Q4 2015)